Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05020899
Other study ID # H-41807
Secondary ID 1R21CA243835-01A
Status Completed
Phase N/A
First received
Last updated
Start date February 24, 2022
Est. completion date August 1, 2023

Study information

Verified date October 2023
Source Boston Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this two arm randomized clinical trial (RCT) is to test if a smoking cessation program called Quit for Life (QFL) which was developed by the investigators is effective for patients in China with HIV who smoke. This program is designed to suit the needs of people with HIV who smoke in China. Eligible participants who provide consent will be randomized into either the QFL or the Control group. The QFL group will receive a quit smoking program that lasts for 8 weeks with two parts- 1. 4 sessions with a trained counselor who will discuss the participants' smoking habits and strategies to help them quit. 2. Messages sent to the participants' cell phone using WeChat. The Control group will not have sessions with a trained counselor or receive messages sent to their cell phone. Both groups will be offered nicotine replacement therapy and a self-help guide with information about quitting smoking.


Recruitment information / eligibility

Status Completed
Enrollment 109
Est. completion date August 1, 2023
Est. primary completion date August 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - HIV seropositive (by being at the HIV clinic and receiving care) - Receiving ART treatment from the clinic (by being at the HIV clinic and receiving care) - Smokes = 5 cigarettes per day - Able to speak and read in Mandarin Chinese - Self-reported anticipate to receive ART treatment from the clinic for at least 9 months - Own a cell phone - Be willing to set a quit date within 1 month after baseline assessment Exclusion Criteria: - Self-reported using other smoking cessation program or medication - Having a serious health problem that may make them unsuitable to stay in the study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Sessions with a trained counselor
4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.
Other:
Cell phone messages
Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time
Offered nicotine replacement therapy
Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).
Self-help guide for quitting smoking
Participants will be offered a self-help guide with information about quitting smoking.

Locations

Country Name City State
China Guangxi Medical University Guangxi Nanning
United States Boston Medical Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Boston Medical Center National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type Measure Description Time frame Safety issue
Other Intervention Satisfaction at 8 Weeks Participant satisfaction with the intervention will be assessed using an investigator-developed questionnaire 8 weeks
Other Intervention Satisfaction at 12 Weeks Participant satisfaction with the intervention will be assessed using an investigator-developed questionnaire 12 weeks
Primary Number of Participants With Biochemically Verified Smoking Cessation Defined as not smoking during the previous 7 days, not even a puff, validated by measuring CO level (<8ppm) in the exhaled air 12 weeks
Secondary Number of Participants That Self Reported Smoking Cessation at 8 Weeks Participants will report if they did not smoke in the previous 7 days by answering questions in an interviewer-administered questionnaire. 8 weeks
Secondary Number of Participants That Self Reported Smoking Cessation at 12 Weeks Participants will report if they did not smoke in the previous 7 days by answering questions in an interviewer-administered questionnaire. 12 weeks
Secondary Change in Number of Cigarettes Smoked in the Previous 30 Days at 8 Weeks Participants will report the number of cigarettes they smoked in the previous 30 days by answering questions in an interviewer-administered questionnaire. baseline, 8 weeks
Secondary Change in Number of Cigarettes Smoked in the Previous 30 Days at 12 Weeks Participants will report the number of cigarettes they smoked in the previous 30 days by answering questions in an interviewer-administered questionnaire. baseline, 12 weeks
Secondary Number of Quit Attempts at 8 Weeks Participants will report the number of quit attempts since the study started by answering questions in an interviewer-administered questionnaire. 8 weeks
Secondary Number of Quit Attempts at 12 Weeks Participants will report the number of quit attempts since the study started by answering questions in an interviewer-administered questionnaire. 12 weeks
Secondary Adherence to Antiretroviral Treatments (ART) at 8 Weeks ART adherence will be assessed with the investigator developed, interviewer-administered 'Adherence to HIV medicine' questionnaire. This questionnaire assesses degree of adherence to taking HIV medicine on time by selecting a number between 0 and 10, where 0 = never on time [worse outcome] and 10 = always on time [best outcome]. Higher scores are more favorable. 8 weeks
Secondary Adherence to Antiretroviral Treatments (ART) at 12 Weeks ART adherence will be assessed with the investigator developed, interviewer-administered 'Adherence to HIV medicine' questionnaire. This questionnaire assesses degree of adherence to taking HIV medicine on time by selecting a number between 0 and 10, where 0 = never on time [worse outcome] and 10 = always on time [best outcome]. Higher scores are more favorable. 12 weeks
Secondary Quality of Life (QOL) in the Dimensions of Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression at 12 Weeks The EuroQol- 5 Dimension (EQ-5D) will be used to assess QOL. It is a questionnaire with five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a scale of 0 to 100 where 0 means the worst health and 100 means the best health the participant can imagine. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2